Cellular Therapies for Mantle Cell Lymphoma. Transplant Cell Ther 2021 May;27(5):363-370
Date
05/10/2021Pubmed ID
33965173DOI
10.1016/j.jtct.2021.01.026Scopus ID
2-s2.0-85101829198 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Mantle cell lymphoma (MCL) is a subtype of B cell non-Hodgkin lymphoma characterized by a heterogeneous clinical presentation. Patients who demonstrate an objective response to induction therapy(ies) and are eligible for intensive therapies are offered an autologous hematopoietic cell transplant (HCT) as front-line consolidation followed by rituximab maintenance. Allogeneic HCT is an option for younger and fit patients with high-risk disease or in patients who have relapsed after autologous HCT. Recent advances in T cell engineering brought chimeric antigen receptor T cell (CAR T) therapy from the bench to the bedside, with brexucabtagene autoleucel being the first CAR T product approved by the US Food and Drug Administration for use in relapsed/refractory MCL. In this comprehensive review, we summarize the literature on available cellular therapies for MCL and present a treatment algorithm that incorporates HCT, autologous or allogeneic, and CAR T therapies.
Author List
Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MAAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultHematopoietic Stem Cell Transplantation
Humans
Immunotherapy, Adoptive
Lymphoma, Mantle-Cell
Neoplasm Recurrence, Local
Transplantation, Autologous
United States
